Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | RECQL | P46063 | 1/20 | 0.48 |
| ▸ | GPR119 | Q8TDV5 | 8/20 | 0.48 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.46 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.46 |
| ▸ | NAMPT | P43490 | 1/20 | 0.46 |
| ▸ | STS | P08842 | 2/20 | 0.45 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.45 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.45 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.45 |
| ▸ | FNTA | P49354 | 1/20 | 0.45 |
| ▸ | FNTB | P49356 | 1/20 | 0.45 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL833367 | 0.88 | ALDH1A1 (0.53) | HPGDGPR119DDB1CRBNNAMPT | |
| SCHEMBL3055188 | 0.86 | DDB1 (0.52) | GPR119DDB1CRBNNAMPTUCHL1 | |
| SCHEMBL31420680 | 0.86 | DDB1 (0.52) | GPR119DDB1CRBNNAMPTUCHL1 | |
| SCHEMBL30895649 | 0.84 | HPGD (0.62) | HPGDRECQLGPR119NAMPTSTS | |
| SCHEMBL26130562 | 0.84 | HPGD (0.62) | HPGDRECQLGPR119NAMPTSTS | |
| SCHEMBL1867980 | 0.83 | HPGD (0.50) | HPGDRECQLGPR119DDB1CRBN | |
| SCHEMBL834021 | 0.82 | UCHL1 (0.64) | DDB1CRBNNAMPTUCHL1 | |
| SCHEMBL2121713 | 0.81 | ESR2 (0.52) | GPR119DDB1CRBNNAMPTUCHL1 | |
| SCHEMBL7641200 | 0.81 | ESR2 (0.52) | GPR119DDB1CRBNNAMPTUCHL1 | |
| SCHEMBL24265580 | 0.79 | MAPK1 (0.49) | GPR119DDB1CRBNNAMPTUCHL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8143284-B2 | 2-cyclohexyl-3-oxo-2,3-dihydro-1H-isoindole-4-carboxamide; allergic encephalitis, arthritis, cardiac and kidney toxicities from doxorubicin-based and platinum-based antineoplastic agents, carcinoma of the breast, central nervous system inflammation, cervical carcinoma, | ABBOTT LABORATORIES (US) | 2012-03-27 | — | — | US | disclosed |
| US-20080108659-A1 | POLY(ADP-RIBOSE)POLYMERASE INHIBITORS | ABBVIE INC. | 2008-05-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080108659-A1 | POLY(ADP-RIBOSE)POLYMERASE INHIBITORS | PARP1, PARP11, PARP2 | HPGD 513/4885RECQL 126/4885GPR119 2169/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.